'Phase 2 study' diaporamas de présentation

Journal reading

1.06k views • 41 slides

Lenalidomide Efficacy

Lenalidomide Efficacy. Alan List, MD Professor of Medicine and Oncology Chief, Division of Malignant Hematology H. Lee Moffitt Cancer Center and Research Institute University of South Florida College of Medicine. Lenalidomide Del 5q MDS Studies. MDS-001 (N = 43 MDS)

442 views • 24 slides

AP23573: Potent mTOR Inhibitor

Updated interim results of a phase 2 study of the mTOR inhibitor AP23573 in patients (pts) with advanced sarcomas of soft tissue or bone Sant P. Chawla, Anthony W. Tolcher, Kamalesh K. Sankhala, Arthur P. Staddon, Camille L. Bedrosian, and George D. Demetri for the AP23573 Sarcoma Study Group

358 views • 23 slides

AP23573: Potent mTOR Inhibitor

Updated interim results of a phase 2 study of the mTOR inhibitor AP23573 in patients (pts) with advanced sarcomas of soft tissue or bone Sant P. Chawla, Anthony W. Tolcher, Kamalesh K. Sankhala, Arthur P. Staddon, Camille L. Bedrosian, and George D. Demetri for the AP23573 Sarcoma Study Group

232 views • 23 slides

Measuring ROI for Research Libraries: Phase II Study @ The University of Tennessee

Measuring ROI for Research Libraries: Phase II Study @ The University of Tennessee ASERL Spring 2010 Membership Meeting Gayle Baker. Phase II. To test Phase I methodology to demonstrate role of library resources in generating research grant income 8 institutions in 8 different countries.

281 views • 17 slides

1 UCSF Comprehensive Cancer Center, San Francisco, CA 2 Arlington Cancer Center, Arlington, TX

Phase 2, Randomized, Open-label Study of Cetuximab and Bevacizumab Alone or in Combination with Fixed-dose Rate (FDR) Gemcitabine as First-line Therapy of Patients with Metastatic Adenocarcinoma of the Pancreas (MPC).

253 views • 17 slides

Final Thoughts

Final Thoughts. -Overall, outcomes in ALL have come a long way since the sixties -Although we can achieve dramatic and sustained responses in childhood ALL, drug refractory relapse is a problem, especially in adults and high risk groups

364 views • 12 slides

Lonial S et al. Proc ASH 2011;Abstract 303.

A Phase 2 Study of Elotuzumab in Combination with Lenalidomide and Low-Dose Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma. Lonial S et al. Proc ASH 2011;Abstract 303. Background.

185 views • 8 slides

175 views • 6 slides